Gene therapy in the treatment of intestinal inflammation

  • Catherine van Montfrans
  • Anje A. te Velde
  • Sander J. H. van Deventer
  • Maria Sol Rodriguez Pena



Local expression of anti-inflammatory or immunoregulatory genes may offer an alternative treatment of gastrointestinal inflammation.


We review the basic requirements for gene therapy, the possible routes of delivery, and the different strategies for specific targeting focusing on gastrointestinal inflammation.


Gene therapy Gastrointestinal inflammation Retroviral vector Interleukin-10 


  1. 1.
    Pawel BR, de Chadarevian JP, Franco ME (1997) The pathology of fibrosing colonopathy of cystic fibrosis: a study of 12 cases and review of the literature. Hum Pathol 28:395–399PubMedGoogle Scholar
  2. 2.
    Cummings OW (2000) Pathology of the adenoma-carcinoma sequence: from aberrant crypt focus to invasive carcinoma. Semin Gastrointest Dis 11:229–237PubMedGoogle Scholar
  3. 3.
    Granger DN, Korthuis RJ (1995) Physiologic mechanisms of postischemic tissue injury. Annu Rev Phys 57:311–332CrossRefGoogle Scholar
  4. 4.
    MacNaughton WK (2000) Review article: new insights into the pathogenesis of radiation-induced intestinal dysfunction. Aliment Pharmacol Ther 14:523–528CrossRefPubMedGoogle Scholar
  5. 5.
    Jankowski JA (2000) Barret's metaplasia. Lancet 356:2079–2085CrossRefPubMedGoogle Scholar
  6. 6.
    Sollid LM (2000) Molecular basis of celiac disease. Annu Rev Immunol 18:53–81PubMedGoogle Scholar
  7. 7.
    Schuppan D (2000) Current concepts of celiac disease pathogenesis. Gastroenterology 119:234–242PubMedGoogle Scholar
  8. 8.
    Heneghan MA, Moran AP (2001) Helicobacter pyroli, Lewis antigens, and inflammation. Gut 48:869CrossRefGoogle Scholar
  9. 9.
    Anderson WF (1998) Human gene therapy. Nature 392:25–30CrossRefGoogle Scholar
  10. 10.
    Hedley ML (2000) Gene therapy of chronic inflammatory disease. Adv Drug Deliv Rev 44:195–207CrossRefPubMedGoogle Scholar
  11. 11.
    Young LS, Mautner V (2001) The promise and potential hazards of adenovirus gene therapy. Gut 48:733–736CrossRefPubMedGoogle Scholar
  12. 12.
    Rennick DM, Fort MM (2000) Lessons from genetically engineered animal models-XII. IL-10-deficient (IL-10 (–/–)) mice and intestinal inflammation. Am J Physiol Gastrointest Liver Physioly 278:G829–G833Google Scholar
  13. 13.
    Deventer SJH van, Elson CO, Fedorak RN, Group CsDS (1997) Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 113:383–389Google Scholar
  14. 14.
    Montfrans C van, et al (2002) Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ. Gut 50:191–195CrossRefPubMedGoogle Scholar
  15. 15.
    Miller DG, Adam MA, Miller AD (1990) Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10:4239–4342Google Scholar
  16. 16.
    Halene S, Kohn DB (2000) Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest. Hum Gene Ther 11:1259–1267CrossRefPubMedGoogle Scholar
  17. 17.
    Bukrinsky MI, Haffar OK (1999) HIV-1 nuclear import: in search of a leader. Front Biosci 4:D772–D781PubMedGoogle Scholar
  18. 18.
    Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173–185PubMedGoogle Scholar
  19. 19.
    Russell WC (2000) Update an adenovirus and its vectors. J Gen Virol 81:2573–2604PubMedGoogle Scholar
  20. 20.
    Walther W, Stein U (2000) Viral vectors for gene transfer—a review of their use in the treatment of human diseases. Drugs 60:249–271PubMedGoogle Scholar
  21. 21.
    Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7:33–40Google Scholar
  22. 22.
    Marshall E (2002) Clinical research: gene therapy a suspect in leukemia-like disease. Science 298:34–35CrossRefPubMedGoogle Scholar
  23. 23.
    Powell SK, Kaloss M, Burimski I, Weaver L, Long Z, Lyons R, McGarrity GJ, Otto E (1999) In vitro analysis of transformation potential associated with retroviral vector insertions. Hum Gene Ther 10:2123–2132CrossRefPubMedGoogle Scholar
  24. 24.
    Amado RG, Chen IS (1999) Lentiviral vectors-the promise of gene therapy within reach? Science 285:674–676Google Scholar
  25. 25.
    Federico M (1999) Lentiviruses as gene delivery vectors. Curr Opin Biotechnol 10:448–453CrossRefPubMedGoogle Scholar
  26. 26.
    Verma IM, Somia N (1997) Gene therapy—promises, problems and prospects. Nature 389:239–242Google Scholar
  27. 27.
    Reiser J (2000) Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 7:910–913CrossRefPubMedGoogle Scholar
  28. 28.
    Vigna E, Naldini L (2000) Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2:308–316CrossRefPubMedGoogle Scholar
  29. 29.
    Trono D (2000) Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther 7:20–23CrossRefPubMedGoogle Scholar
  30. 30.
    Seppen J, Barry SC, Klinkspoor JH, Katen LJ, Lee SP, Garcia JV, Osborne WR (2000) Apical gene transfer into quiescent human and canine polarized intestinal epithelial cells by lentivirus vectors. J Virol 74:7642–7645CrossRefPubMedGoogle Scholar
  31. 31.
    Cheng DY, Kolls JK, Lei D, Noel RA (1997) In vivo and in vitro gene transfer and expression in rat intestinal epithelial cells by E1-deleted adenoviral vector. Hum Gene Ther 8:755–764PubMedGoogle Scholar
  32. 32.
    Lindsay JO, Ciesielski CJ, Feldmann M, Brennan FM (2000) The stable infection of epithelial cell lines and primary rabbit colon cells with an adenovirus encoding murine interleukin-10 (mIL-10) generates bioactive cytokine at therapeutic concentrations. Gastroenterology a 3035Google Scholar
  33. 33.
    Lindsay J, van Montfrans C, Brennan F, van Deventer S, Drillenburg P, Hodgson H, te Velde A, MS RP (2002) IL-10 gene therapy prevents TNBS induced colitis. Gene Ther 9:1715–1721CrossRefPubMedGoogle Scholar
  34. 34.
    Kitani A, Fuss IJ, Nakamura K, Schwartz OM, Usui T, Strober W (2000) Treatment of experimental (trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J Exp Med 192:41–52CrossRefPubMedGoogle Scholar
  35. 35.
    During MJ, Xu R, Young D, Kaplitt MG, Sherwin RS, Leone P (1998) Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med 4:1131–1135CrossRefPubMedGoogle Scholar
  36. 36.
    Lindsay JO, Cathleen J, Ciesielski FMB, Humphrey J, Hodgson (2001) Rectal administration of an adenoviral vector encoding IL-10 induces colonic IL-10 release with minimal anti-adenoviral response. Gastroenterology a 3715Google Scholar
  37. 37.
    Rogy MA, Beinhauer BG, Reinisch W, Huang L, Pokieser P (2000) Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum Gene Ther 11:1731–1741CrossRefPubMedGoogle Scholar
  38. 38.
    Ayuk FA, Li Z, Kuhlcke K, Lindemann C, Schade UM, Eckert HG, Zander AR, Fehse B (1999) Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements. Gene Ther 6:1788–1792CrossRefPubMedGoogle Scholar
  39. 39.
    Movassagh M, Boyer O, Burland M, Leclercq L, Klatzmann D, and Lemoine FM (2000) Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. Hum Gene Ther 11:1189–1200CrossRefPubMedGoogle Scholar
  40. 40.
    Dardalhon V, Jaleco S, Rebouissou C, Ferrand C, Skander N, Swainson L, Tiberghirn P, Spits H, Noraz N, Taylor N (2000) Highly efficient gene tranfer in naive human T cells with a murine leukemia virus-based vector. Blood 96:885–893PubMedGoogle Scholar
  41. 41.
    Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P (1995) T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270:475–480PubMedGoogle Scholar
  42. 42.
    Anderson WF (2000) Gene therapy. The best of times, the worst of times. Science 288:627–629CrossRefPubMedGoogle Scholar
  43. 43.
    Cavazzano-Calvo M, Hacein-Bey S, de Saint Basile G, Gross G, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Le Deist F, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669–672CrossRefPubMedGoogle Scholar
  44. 44.
    Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719–1724CrossRefPubMedGoogle Scholar
  45. 45.
    Chen LZ, Hochwald GM, Huang C, Dakin G, Tao H, Cheng C, Simmons WJ, Dranoff G, Thorbecke GJ (1998) Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1. Proc Natl Acad Sci U S A 95:12516–12521CrossRefPubMedGoogle Scholar
  46. 46.
    Setoguchi K, Misaki Y, Araki Y, Fujio K, Kawahata K, Kitamura T, Yamamoto K (2000) Antigen-specific T cells transduced with IL-10 ameliorate experimentally induced arthritis without impairing the systemic immune response to the antigen. J Immunol 165:5980–5986PubMedGoogle Scholar
  47. 47.
    van Montfrans C, Hooijberg E, Rodriguez-Pena M, de Jong E, Spits H, te Velde A, van Deventer S (2002) Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin 10 gene transfer. Gastroenterology 123:1877–1888CrossRefPubMedGoogle Scholar
  48. 48.
    Montfrans C van, Rodriguez-Pena M, Pronk I, ten Kate F, te Velde A, van Deventer S (2002) Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology 123:1865–1876CrossRefPubMedGoogle Scholar
  49. 49.
    Timmerman JM, Levy R (1999) Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50:507–529PubMedGoogle Scholar
  50. 50.
    Bonini C, Lee SP, Riddell SR, Greenberg PD (2001) Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 166:5250–5257PubMedGoogle Scholar
  51. 51.
    Legge KL, Gregg RK, Maldonado-Lopez R, Li L, Caprio JC, Moser M, Zaghouani H (2002) On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J Exp Med 196:217–227CrossRefPubMedGoogle Scholar
  52. 52.
    Lipscomb MF, Masten BJ (2002) Dendritic cells: immune regulators in health and disease. Physiol Rev 82:97–130PubMedGoogle Scholar
  53. 53.
    Feili-Hariri M, Dong X, Alber S, Watkins S, Salter R, Morel P (1999) Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 48:2300–2308PubMedGoogle Scholar
  54. 54.
    Khoury S, Gallon L, Chen W, Betres K, Russell M, Hancock W, Carpenter C, Sayegh M, Weiner H (1995) Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med 182:357–366PubMedGoogle Scholar
  55. 55.
    Vile RG, Sunassee K, Diaz RM (1998) Strategies for achieving multiple layers of selectivity in gene therapy. Mol Med Today 4: 84–92PubMedGoogle Scholar
  56. 56.
    Peng KW (1999) Strategies for targeting therapeutic gene delivery. Mol Med Today 5:448–453CrossRefPubMedGoogle Scholar
  57. 57.
    Peng KW, Russell SJ (1999) Viral vector targeting. Curr Opin Biotechnol 10:454–457CrossRefPubMedGoogle Scholar
  58. 58.
    Sweetser DA, Birkenmeier EH, Hoppe PC, McKeel DW, Gordon JI (1988) Mechanisms underlying generation of gradients in gene expression within the intestine: an analysis using transgenic mice containing fatty acid binding protein-human growth hormone fusion genes. Genes Dev 2:1318–1332PubMedGoogle Scholar
  59. 59.
    Marin M, Noel D, Piechaczyk M (1997) Towards efficient cell targeting by recombinant retroviruses. Mol Med Today 3:396–403CrossRefPubMedGoogle Scholar
  60. 60.
    Sommerfelt M (1999) Retrovirus receptors. J Gen Virol 80:3049–3064PubMedGoogle Scholar
  61. 61.
    Gallardo H, Tan C, Ory D, Sadelain M (1997) Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90:952–957PubMedGoogle Scholar
  62. 62.
    Lodge R, Subbramanian RA, Forget J, Lemay G, Cohen EA (1998) MuLV-based vectors pseudotyped with truncated HIV glycoproteins mediate specific gene transfer in CD4+ peripheral blood lymphocytes. Gene Ther 5:655–664CrossRefPubMedGoogle Scholar
  63. 63.
    Hanauer SB, Dassopoulos T (2001) Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med 52:299–318CrossRefPubMedGoogle Scholar
  64. 64.
    Ghosh S, May MJ, Kopp EB (1998) NFkB and rel proteins: evolutionarily conserved mediators of immune response. Annu Rev Immunol 16:225–260PubMedGoogle Scholar
  65. 65.
    Makarov SS (2000) NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today 6:441–448PubMedGoogle Scholar
  66. 66.
    Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:7–11PubMedGoogle Scholar
  67. 67.
    Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE (1999) The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17:701–738CrossRefPubMedGoogle Scholar
  68. 68.
    Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765Google Scholar
  69. 69.
    Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16:27–55PubMedGoogle Scholar
  70. 70.
    Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17:331–367Google Scholar
  71. 71.
    Hasko G, Szabo C (1999) IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses. Br J Pharmacol 127:1295–1304PubMedGoogle Scholar
  72. 72.
    Coyle AJ, Gutierrez-Ramos JC (2001) The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2:203–209CrossRefPubMedGoogle Scholar
  73. 73.
    Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ (1996) Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 14:591–617PubMedGoogle Scholar
  74. 74.
    Siegel RM, Chan FK, Chun HJ, Lenardo MJ (2000) The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 1:469–474CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Catherine van Montfrans
    • 1
  • Anje A. te Velde
    • 1
  • Sander J. H. van Deventer
    • 1
  • Maria Sol Rodriguez Pena
    • 1
  1. 1.Department of Experimental Internal MedicineAcademic Medical CenterAmsterdamThe Netherlands

Personalised recommendations